Results 171 to 180 of about 6,757 (189)

Leveraging cDC1 biology and function for enhanced immunotherapy

Journal of Experimental Medicine
Conventional type 1 dendritic cells (cDC1s) promote antitumor immunity through efficient cross-presentation of tumor antigens and production of key mediators. Crucially, in the tumor microenvironment, cDC1s orchestrate immune hubs and signaling axes that support T cell responses and are associated with improved patient outcomes.
Ross W. Ward, Uddipan Kar, Sreekumar Balan, Nina Bhardwaj   +3 more
openaire   +1 more source

IRF8 deficiency induces the transcriptional, functional, and epigenetic reprogramming of cDC1 into the cDC2 lineage

Immunity, 2022
Allan Mowat, Thorsten Joeris, Knut Kotarsky   +2 more
exaly  

Faculty Opinions recommendation of cDC1 Vaccines Drive Tumor Rejection by Direct Presentation Independently of Host cDC1.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature, 2022
openaire   +1 more source

Commensal Cryptosporidium colonization elicits a cDC1-dependent Th1 response that promotes intestinal homeostasis and limits other infections

Immunity, 2021
Chyi-Song Hsieh, L David Sibley, Lindsey E Fox   +2 more
exaly  

A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunity

Cancer Cell, 2023
Philippa Meiser
exaly  

Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses

Immunity, 2023
Anne Zaremba, Philippa Meiser
exaly  

Mechanisms of Cross-Presentation by cDC1s

2020
openaire   +1 more source

Platelets interact with CD169+ macrophages and cDC1 and enhance liposome-induced CD8+ T cell responses

Frontiers in Immunology, 2023
Yvette Van Kooyk, Joke M M Den Haan, Cees Van Kooten   +2 more
exaly  

Immunoactive nanoparticle boosted cDC1 for in situ cancer immunotherapy

PURPOSE: Cancer immunotherapy, which aims to stimulate the immune system to induce antigen specific immune responses against cancers, has emerged as a promising approach for cancer intervention. However, eliciting an effective antitumor immune response is hindered by the scarcity of appropriate antigen-presenting cells (APCs) and their impaired ...
openaire   +1 more source

cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity

Nature, 2020
Robert Schreiber, Theresa Murphy, Prachi Bagadia   +2 more
exaly